A Tempo-geographic Analysis of Global COVID-19 Epidemic Outside of China

Huipeng Liao; Gifty Marley; Yafei Si; Zaisheng Wang; Yewei Xie; Cheng Wang; Weiming Tang

doi:10.1101/2020.03.20.20039602

Abstract

Background Understanding the global epidemic trends, geographic distribution, and transmission patterns of COVID-19 contribute to providing timely information for the global response of the epidemic. This study aims to understand the global pandemic geospatial patterns and trends and identify new epicenters requiring urgent attention.

Methods Data on COVID-19 between 31^st Dec. 2019 and 14^th Mar. 2020 was included. The epidemic trend was analyzed using joinpoint regressions; the growth of affected countries was by descriptive analysis; and the global distribution and transmission trend by spatial analysis. Findings: The number of new cases in the regions outside of China slowly increased before 24^th Feb. and rapidly accelerated after 24^th Feb. Compared to China, other affected countries experienced a longer duration of a slow increase at the early stage and rapid growth at the latter stages. The first apparent increase in the number of affected countries occurred from 23^rd Jan to 1^st Feb, and the second apparent increase started from 25^th Feb. The fist COVID-19 cases reported by countries from 28^th Feb. were mainly imported from Europe. The geographic distribution changed from single-center (13^th Jan. - 20^th Feb.) to multi-centers pattern (20^th Feb. – 14^th Mar.). More countries were affected with COVID-19 and developed local transmission.

Interpretation The joinpoint regression and geospatial analysis indicated a multi-center pandemic of COVID-19. Strategies to prevent the new multiple centers as well as prevent ongoing transmission are needed.

Funding NIH.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Source of funding: This work was supported by the National Key Research and Development Program of China (2017YFE0103800), NIMH (R34MH119963), National Science and Technology Major Project (2018ZX10101-001-001-003), and the National Nature Science Foundation of China (81903371). Tang acknowledged their kindly supports. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. The authors thank all the people who contributed to this study.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data are publicly available at World Health Organization, China's National Health Commissions, and GADM.org

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

https://gadm.org/download_country_v3.html

http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.